About this page: This is the class-wide safety reference for all hyaluronic acid (HA) dermal fillers distributed by fillersfairy.com. It applies to Tesoro Rouge, Belotero, Restylane, Juvederm, Volbella, Kysse, Bonetta, Dermalax, Neuramis, Revolax, Stylage, Yvoire, and other HA dermal fillers in our catalogue. Each product page links to this reference rather than repeating the full safety content. Always refer to the manufacturer’s official Instructions for Use (IFU) before clinical administration. Non-HA fillers (calcium hydroxylapatite, poly-L-lactic acid, polycaprolactone, body fillers) have different risk profiles and are covered by separate safety pages.
Intended Users & Scope of Use
Hyaluronic acid dermal fillers are prescription medical devices. Administration is restricted to licensed healthcare professionals operating within their scope of practice — physicians, plastic surgeons, dermatologists, registered aesthetic nurses (under supervision per local regulations), and trained aesthetic practitioners with documented dermal filler training. The administering practitioner is responsible for patient screening, dose calculation, aseptic technique, injection placement, and post-treatment management.
HA dermal fillers are not for personal use, self-injection, administration by non-medical personnel, or retail consumer sale. They are distributed exclusively for clinical and aesthetic medical use.
Contraindications (Absolute & Relative)
Do not administer HA dermal fillers to patients with the following:
Known hypersensitivity to hyaluronic acid, lidocaine (where present), gram-positive bacterial proteins (residual from HA fermentation), or any product excipient
Pregnancy or breastfeeding — insufficient safety data; potential foetal or neonatal exposure not characterized
Active local infection — cellulitis, dermatitis, herpes outbreak, acne lesions, or any open wound at or adjacent to the planned injection site
Bleeding or coagulation disorders — haemophilia, thrombocytopenia, von Willebrand disease, and similar conditions
Active autoimmune disease — particularly during flares (lupus, rheumatoid arthritis, scleroderma)
History of severe allergic reactions or anaphylaxis to injectable medications
History of hypertrophic scarring or keloid formation
Patients under 18 years of age for cosmetic indications (under 21 in some jurisdictions per local labelling — e.g. FDA-approved HA fillers are indicated for adults 21+)
Recent dental procedures within the last 2 weeks, or planned dental work within the next 2 weeks (perioral and lip injections)
Recent laser, chemical peel, microneedling, or aggressive facials on the target area within the last 2 weeks
Permanent filler or implant already present at the planned injection site — increased granuloma and biofilm risk
Active body dysmorphic disorder or unrealistic expectations — relative contraindication; thorough psychological screening recommended
Possible Side Effects
Common reactions (mild, generally self-resolving within 1–7 days; typically local to the injection site):
Pain, bruising, redness, swelling, or pinpoint bleeding at injection sites
Tenderness or mild discomfort persisting 24–72 hours
Itching or transient skin sensitivity
Mild asymmetry or palpable lumps that smooth out with gentle massage
Localized firmness for the first 1–2 weeks as the product integrates
Headache (mild, infrequent)
Less common reactions:
Prolonged swelling beyond 7 days (more common in periocular and lip treatments)
Delayed hypersensitivity reactions (days to weeks post-injection)
Herpes simplex reactivation in predisposed patients (perioral and lip treatments)
Local injection-site infection
Visible Tyndall effect — blue-grey discoloration from superficial placement (most common around tear troughs and lips)
Rare but serious — seek immediate medical assessment:
Severe allergic reactions, including anaphylaxis (urticaria, angioedema, breathing difficulty, hypotension)
Granuloma formation (typically months post-injection; may require corticosteroid injection or surgical removal)
Biofilm-related delayed infections (weeks to months post-injection; require specific microbiological assessment)
Vascular complications — see dedicated section below
Skin necrosis at or near the injection site
Permanent or persistent disfigurement
⚠ Vascular Complication Warning (Class-Wide)
This is the most serious risk associated with all hyaluronic acid dermal fillers and is required disclosure across regulatory jurisdictions (FDA, EMA, KFDA). Awareness of vascular complication risk is mandatory for every practitioner before administering HA filler.
The Risk
Accidental intravascular injection — when filler enters an artery or vein rather than the intended tissue plane — can cause vascular occlusion. The blocked vessel deprives downstream tissue of blood supply, producing:
Tissue ischaemia — pale, mottled, or dusky discoloration at and beyond the injection site
Tissue necrosis — death of skin and underlying soft tissue if ischaemia is not promptly reversed; may result in permanent scarring
Visual disturbance or vision loss — if filler enters the facial arterial network with retrograde flow to the ophthalmic artery; vision loss may be sudden, painful, and permanent. The forehead, glabella, and nasal regions carry the highest ophthalmic risk; lip and cheek regions carry significant but lower risk
Cerebral embolism — extremely rare but reported; stroke-like symptoms require emergency hospital care
High-Risk Anatomical Areas
All facial filler injection carries some vascular risk, but particular caution is required in:
Glabella and forehead — supratrochlear and supraorbital arteries with anastomoses to the ophthalmic artery
Nose and nasolabial folds — angular and dorsal nasal arteries
Tear trough and infraorbital area — infraorbital and angular arteries
Lips — superior and inferior labial arteries (branches of the facial artery)
Temples — superficial temporal artery
Practitioner Safeguards
Know the anatomy — review facial vascular maps for every region you treat
Aspirate before each injection — a brief negative pull to check for blood return before depressing the plunger
Use slow retrograde injection technique — moving the needle backwards while depositing small amounts reduces intravascular bolus risk
Inject low volumes per pass — typically 0.05–0.1 ml at a time, never large boluses
Prefer blunt cannula over sharp needle where anatomically feasible — cannulas reduce (but do not eliminate) vessel puncture risk
Keep hyaluronidase immediately available — every clinic administering HA filler must stock hyaluronidase for emergency dissolution. Dose typically 500–1500 IU per affected area, repeated as needed
Maintain emergency protocol awareness — every team member should know the steps for suspected vascular occlusion or visual symptoms
Warning Signs Requiring Immediate Intervention
Practitioners must recognise and act on these immediately — minutes matter:
Severe, disproportionate pain — out of proportion to expected injection discomfort
Skin blanching — sudden white appearance at or beyond injection site
Mottled or dusky discoloration — patchy livedo-like pattern indicating ischaemia
Vision change — blurred vision, visual field loss, diplopia, or complete vision loss
Severe headache, especially with vision change — possible cerebral involvement
Speech difficulty, weakness, or facial droop — stroke warning signs
Emergency Response
Stop the injection immediately. Inject hyaluronidase liberally throughout the affected vascular territory. Apply warm compresses to promote vasodilation. Massage the area gently. Administer aspirin if not contraindicated. Document the time of onset, area affected, and intervention. For any vision change, refer immediately to ophthalmology and emergency services — do not wait. The window for successful intervention in vision-threatening complications is measured in minutes to hours, not days.
Storage & Handling Requirements
Store at 2–25 °C in original packaging (specific range varies by product — verify each manufacturer’s label)
Keep away from direct sunlight and heat sources
Do not freeze — freezing damages the gel structure and renders the product unusable
Inspect the syringe before use — check for clarity, absence of discoloration, intact seal, undamaged plunger, and valid expiration date
Use immediately after opening — single-use sterile devices; partial syringes cannot be retained or reused
Shelf life — typically 24–36 months from the manufacturing date, varies by product
Do not use if the packaging is damaged, the seal is broken, the gel appears discoloured or contaminated, or the expiration date has passed
Patient Aftercare Instructions
Practitioners should provide patients with the following post-treatment guidance:
0–4 hours: Stay upright. Avoid lying flat, bending at the waist, or vigorous facial movement
0–24 hours: Do not touch, press, or massage the treated area unless instructed by the practitioner. Cold compresses may be applied gently to reduce swelling. Avoid alcohol consumption
0–48 hours: Avoid strenuous exercise, saunas, hot tubs, hot showers, and direct sun exposure. Avoid extreme facial expressions where possible
0–2 weeks: No laser treatments, chemical peels, microneedling, dermabrasion, or aggressive facials on the treated area. No elective dental procedures (perioral injections)
Lip-specific aftercare: Avoid prolonged lip-on-lip contact for the first 24 hours. Use gentle lip balm only — no exfoliating or matte lip products for the first week
Sleep position: Head slightly elevated for the first 1–2 nights to minimize swelling
Always: Contact the treating practitioner immediately if any vision change, severe pain, skin blanching, mottling, signs of infection, or severe allergic symptoms develop
Aftercare guidance may vary by treatment area, product, and practitioner protocol. Patients should follow specific instructions from their treating professional.
🚨 When to Seek Emergency Care
Patients should be informed that the following symptoms require immediate medical attention — do not wait for the next clinic visit:
Sudden vision change — blurred vision, double vision, or loss of vision
Severe, persistent, or disproportionate pain at or beyond the injection site
Skin blanching (sudden white appearance) or mottled/dusky discoloration
Signs of severe allergic reaction — facial swelling, difficulty breathing, swelling of the tongue or throat, generalized rash, dizziness, or fainting
Severe headache, particularly accompanied by vision change
Signs of infection — fever, expanding redness, pus, increasing warmth, or worsening pain after 48–72 hours
Stroke warning signs — facial droop, arm or leg weakness, speech difficulty
Regulatory Status
The HA dermal fillers distributed by fillersfairy.com include products manufactured in multiple jurisdictions — South Korea (KFDA approval), Europe (CE marking), and the United States (FDA approval for select brands). Regulatory status varies by individual product and country.
Not every product in our catalogue is FDA-approved or CE-marked. Many Korean HA dermal fillers (Tesoro, Neuramis, Revolax, Bellast, Bonetta, Dermalax, etc.) hold KFDA approval and CE marking but are not FDA-approved for sale in the United States. Buyers are solely responsible for verifying the legal status of any specific product in their jurisdiction before purchase, importation, or clinical use.
Importation of dermal filler products without proper regulatory approval may be illegal in some jurisdictions and can lead to package seizure, customs penalties, or other legal consequences. Fillersfairy.com is not responsible for customs issues, refused shipments, or legal action arising from unauthorised importation.
Liability Disclaimer
Fillersfairy.com is a distributor of aesthetic medical products. We do not manufacture the products we distribute and we do not provide medical advice. All information on this page and on individual product pages is provided for informational purposes only and does not constitute medical, clinical, dosing, or treatment advice.
Licensed practitioners are solely responsible for: patient selection and screening, treatment planning, dose calculation, aseptic handling, injection administration, post-treatment patient management, emergency response, and all aspects of clinical care. Fillersfairy.com assumes no responsibility for clinical outcomes, complications, adverse events, dose errors, misuse, or any consequence arising from the administration of products it distributes.
Always refer to the manufacturer’s official Instructions for Use (IFU) for the specific product being administered. The manufacturer’s IFU is the authoritative source for indications, contraindications, dosing, administration technique, warnings, and adverse reactions.
This page is updated periodically and reflects general class-wide safety standards for hyaluronic acid dermal fillers as of the last revision date. Individual product labelling may contain additional warnings or contraindications not reflected here.
By purchasing hyaluronic acid dermal filler products from fillersfairy.com, you confirm that you are a licensed medical professional, you have reviewed this safety information, and you accept full responsibility for clinical use.
